Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.

J Clin Oncol · 2023 · PMC9937097 · PMID 36327426

Europe PMC DOI

hedged sentences

0.0758

closest p · 1.5× alpha

0.0758

boldest claim

The sentences

did not reach statistical significanceP = .0758so close (0.05 < p ≤ 0.1)

RESULTS PFS was significantly improved with D + CT versus CT (hazard ratio [HR], 0.74; 95% CI, 0.62 to 0.89; P = .0009; median, 5.5 v 4.8 months); a trend for improved OS did not reach statistical significance (HR, 0.86; 95% CI, 0.72 to 1.02; P = .0758; median, 13.3 v 11.7 months; 24-month OS, 29.6% v 22.1%).

also in 111,027 other papers

a positive trendno p-value reported

DISCUSSION In POSEIDON, first-line D + CT significantly improved PFS versus CT in patients with mNSCLC, with a positive trend for OS improvement that did not reach statistical significance.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.